Lowering of blood pressure – by treatment of other risk factors

Česká verzia

Authors: Miroslav Souček ^1,2
Authors place of work: II. interní klinika LF MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Miroslav Souček, CSc. ¹; Mezinárodní centrum klinického výzkumu – ICRC FN u sv. Anny v Brně, ředitel Gorazd B. Stokin, M. D., MSc., Ph. D ²
Published in the journal: Vnitř Lék 2015; 61(7-8): 717-720
Category: Vanýsek´s day 2015

Summary

Reaching the target value of blood pressure is still a big problem. A mere 30 % of treated hypertensives reach blood pressure values < 140/90 mm Hg. Hypertensive patients often exhibit further risk factors – diabetes mellitus, dyslipoproteinemia, excess weight and obesity, all of which are included in the definition of metabolic syndrome. The cardiovascular risks associated with the individual risk factors are not summed, they are multiplied. Unfortunately, the individual risk factors have been treated separately until now. However, there is an effort aimed at treating individual risk factors in the way that may positively affect others. The study focuses on the treatment of type 2 diabetes mellitus, dyslipidemia, excess weight and obesity taking account of possible influencing of blood pressure values.

Key words:
type 2 diabetes mellitus – hypertension – metabolic syndrome – excess weight – obesity

Zdroje

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–2497.

2. Rosolová H et al. Kardiometabolický syndrom. In: Rosolová H (ed). Preventivní kardiologie v kostce. Axonite CZ: Praha 2013: 120–158. ISBN 978–80–904899–5-0.

3. Yusuf S, Haewken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–952.

4. Haluzík M. Antihypertenzní účinky inkretinové léčby u diabetes mellitus 2. typu. In: Widimský J Jr (ed). Arteriální hypertenze – současné klinické trendy XI. Triton: Praha 2013: 2–39. ISBN 978–80–7387–675–3.

5. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1): 275–286.

6. Zinman B, Schmidt WE, Moses A et al. Achieving a clinically relevant composite outcome of an HbA1c of pod 7% without weigt gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012; 14(1): 77–82.

7. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LESD-6). Lancet 2009; 374(9683): 39–47.

8. White WB, Cannon CHP, Heller ST et al. EXALMINE investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 2013; 369(14): 1327–1335.

9. Scirica BM, Bhatt DL, Braunnwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369(14): 1317–1326.

10. Weber MA, Mansfield TA, Alessi F et al. Effects of Dapagliflozin on Blood Pressure in Diabetic Patients With Hypertension Inadequately Controlled by a Renin-Angiotensin System Blocker. Circulation 2013; 128: A13144. Prezentováno na Annual Meeting of the American Heart Association, Dallas, USA, 2013: Poster 2095. Abstrakt dostupný z WWW: <http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A13144>.

11. Weber MA, Mansfield TA, T’joen C et al. Dapagliflozin for Reduction of Blood Pressure in Diabetic Patients Inadequately Controlled With Combination Antihypertensive Regimen. Circulation 2013; 128: A13165. Prezentováno na Annual Meeting of the American Heart Association, Dallas, USA, 2013: Poster 2097. Abstrakt dostupný z WWW: <http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A13165?sid=9929df8a-d615–47d0-a4cc-59a5d8d01277>.

12. Svačina Š. Nová antidiabetika, jejich tolerance a bezpečnost. In: Widimský J Jr (ed). Arteriální hypertenze – současné klinické trendy XIII. Triton: Praha 2015: 9–14. ISBN 978–80–7387–883–2.

13. Nickenig G. New Drugs and Technologies. Should angiotensin II receptor blockers and statins be combined? Circulation 2004; 110: 1013–1020. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000139857.85424.45>.

14. Vrablík M. Hypertenze a dyslipidemie: synergie v patogenezi i prevenci aterosklerózy. In: Widimský J Jr (ed). Arteriální hypertenze – současné klinické trendy XII. Praha: Triton 2014: 47–55. ISBN 978807387763.

15. Borghi C, Dormi A, Veronesi M et al. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148(2): 285–292. Dostupné z WWW: <http://www.medscape.com/viewarticle/489877>.

16. Prandin MG, Cicero AF, Dormi A et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice. Nutr Metab Cardiovasc Dis 2010; 20(7): 512–518.

17. Juncos LI, Jucos LA, Garcia NH. The antihypertensive actions of statins: modulation by salt intake. Am J Hypertens 2012; 25(11): 1140–1148.

18. Banach M, Nikfar S, Rahimi R et al. The effects of statins on blood pressure in normotensive or hypertensive subjects – a meta-analysis of randomized controlled trials. Int J Cardiol 2013; 168(3): 2816–2824.

19. Sucharda P. Vedou výkony metabolické chirurgie k dlouhodobému ovlivnění krevního tlaku? In: Widimský J Jr (ed). Arteriální hypertenze – současné klinické trendy XIII. Triton: Praha 2015: 23–29. ISBN 978–80–7387–883–2.

20. Staessen J, Fagard R, Emery A. The relationship between body weight and blood pressure. J Hum Hypertens 1988; 2(4): 207–217.

21. Sugerman HJ, Wolfe LG, Sica DA et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003; 237(6): 751–756.

22. Hinojosa MW, Varela JE, Smith BR et al. Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 2009; 13(4): 793–797.

23. Ricci C, Gaeta M, Rausa E et al. Long-Term Effects of Bariatric Surgery on Type II Diabetes, Hypertension and Hyperlipidemia: A Meta-Analysis and Meta- Regression Study with 5-Year Follow-Up. Obes Surg 2015; 25(3): 397–405.

24. Wilhelm SM, Young J, Kale-Pradhan PB. Effect of bariatric surgery on hypertension: a meta-analysis. Ann Pharmacother 2014; 48(6): 674–682.

25. Cífková R, Bruthans J, Adámková V. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. Cor Vasa 2011; 53(4–5): 220–229.